ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

About this update from Immunitybio, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/34d7c9b43889c31ebf6d5dd626ed7075"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eTF7GmMwqwx9jVxUB3nQzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/34d7c9b43889c31ebf6d5dd626ed7075","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Interim analysis requested by the FDA demonstrated a statistically significant improvement in duration of complete response with ANKTIVA plus BCG, with no significant safety signals observed","length":190,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company anticipates submitting a biologics license application (BLA) to the U.S. FDA by Q4 2026","length":95,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expanded access program (EAP) of recombinant BCG is ongoing, with 580 patients currently enrolled throughout the U.S.","length":117,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":534,"olType":false},{"type":"text","content":"CULVER CITY, Calif., February 26, 2026--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors.","length":435,"tagName":"p"},{"type":"text","content":"The QUILT 2.005 trial (NCT02138734), which completed enrollment ahead of schedule, includes 366 patients randomized to receive either BCG alone, the current standard-of-care for NMIBC CIS, or ANKTIVA in combination with BCG. An interim analysis requested by the U.S. Food and Drug Administration (FDA) demonstrated that treatment with ANKTIVA plus BCG resulted in a statistically significant improvement in the duration of complete res...

More updates from Immunitybio, Inc.